Markt oder Branche auswählen:
| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| ULTRAGENYX | 22 | - | -1,19 % | ||
| PRAXIS PRECISION MEDICINES | 11 | - | 0,00 % | ||
| ROYALTY PHARMA | 6 | - | +0,12 % | ||
| BIONTECH | 4 | 13 | +0,12 % | ||
| BIOMARIN PHARMACEUTICAL | 3 | 12 | +0,27 % | ||
| DYNAVAX | 3 | 4 | -0,19 % | ||
| AMICUS THERAPEUTICS | 3 | 1 | -0,82 % | ||
| AUTOLUS THERAPEUTICS | 3 | - | -1,88 % | ||
| PTC THERAPEUTICS | 2 | 4 | 0,00 % | ||
| OMEROS | 2 | - | -0,71 % |
- 24 h
- 7 Tage
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03:36 | Royalty Pharma Acquires Remaining Evrysdi Royalties From PTC Therapeutics | 270 | AFX News | SOUTH SAN FRANCISCO (dpa-AFX) - Royalty Pharma plc (RPRX) announced that it has acquired the final portion of PTC Therapeutics' remaining royalty interest in Roche's Evrysdi. The transaction... ► Artikel lesen | |
| 03:26 | Mesoblast Secures Lower-Cost Credit Line, Retires Senior Debt | 1 | Finance News Network | ||
| 03:05 | Why DroneShield, IPD, Mesoblast, and Woodside shares are charging higher today | 10 | The Motley Fool Australia | ||
| 02:31 | Why Praxis Precision Medicines Stock Popped Today | 1 | The Motley Fool | ||
| 01:26 | Mesoblast Secures US$75 Million Credit Line, Refinances Debt | 1 | Finance News Network | ||
| 01:00 | Mesoblast Limited: Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line | 1 | GlobeNewswire (USA) | ||
| 00:21 | MESOBLAST LIMITED: Proposed issue of securities - MSB | 1 | ASX | ||
| 00:02 | MESOBLAST LIMITED: Mesoblast Enters into Non-Dilutive Lower Cost 5-Year Credit | 1 | ASX | ||
| Mo | Royalty Pharma sichert sich vollständige Evrysdi-Lizenzgebühren - Aktie legt zu | 1 | Investing.com Deutsch | ||
| Mo | Royalty Pharma buys remaining royalty interest in Roche drug Evrysdi | 3 | Seeking Alpha | ||
| Mo | Royalty Pharma sichert sich vollständige Evrysdi-Tantiemen für 240 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| Mo | Verastem ends trial of Avmapki Fakzynja combo with Amgen's Lumakras in NSCLC | 2 | Seeking Alpha | ||
| Mo | $100 Invested In argenx 5 Years Ago Would Be Worth This Much Today | 2 | Benzinga.com | ||
| Mo | Royalty Pharma acquires final portion of Evrysdi royalty for $240 million | 1 | Investing.com | ||
| Mo | Royalty Pharma plc: Royalty Pharma Acquires Remaining Royalty Interest in Roche's Evrysdi for $240 Million and Potential Milestones | 6 | GlobeNewswire (USA) | ||
| Mo | Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today | 1 | The Motley Fool | ||
| Mo | Sanofi - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| Mo | BTIG bestätigt Kaufempfehlung für Apogee Therapeutics angesichts positiver Aussichten | 1 | Investing.com Deutsch | ||
| Mo | BTIG reiterates Buy rating on Apogee Therapeutics stock amid positive outlook | 1 | Investing.com | ||
| Mo | Quantum-Si Inc - 8-K, Current Report | - | SEC Filings |
1 2 3 4 5 Weiter >>
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .